The announcement dated 02/09/14 highlights the work Phylogica and IMB are working on - a key intracellular 'master switch' protein known as SOX18 (1).
In yesterday's newsletter the company highlighted that they have already demonstrated that their drug delivery process, together with OmoMyc can kill drug resistant breast cancer cells in vitro and improve the efficacy of existing anti-cancer drugs. Refer to page 1 of the newsletter. (2) Note also, that page 42 of the recent Technical Presentation (May 2015) highlights that the company have already identified >15 Phylomer hits which are more active than Omomyc. (3)
If we go back to February's newsletter the company highlighted this excerpt....
One of the most important classes of oncogene are the “Transcription Factors”. These act as master regulators relaying critical messages within the cell and controlling the switching on and off of many other genes that drive cancer and other diseases. (4)
So here we have two key intracellular 'master switches' that the company in collaboration with leading scientists in their respective fields in world class labs are targeting.
The market may not be putting too much value on the company's peptide delivery technology platform, but, what my attention is on is... what these numerous collaborators, experts in their field are seeing in Phylogica's technology platform.
Put simply, our peptide delivery technology is enabling a far greater range of smart drugs, or biologics, to reach important protein targets inside cells. This is a new frontier in drug development that promises to unlock the potential for smart drugs to treat diseases, such as cancer, more effectively and with fewer side-effects. (4)
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)